Acute coronary syndromes
KEYWORDS: people, coronary, acute, pci, risk, acute coronary, therapy, recommendations, committee, evidence, angina, unstable, nstemi, unstable angina, offer

2010). Management when PCI is not indicated 1.2.20 Consider conservative management without early coronary angiography for people with unstable angina or NSTEMI who have a low risk of adverse cardiovascular events (predicted 6-month mortality 3.0% or less). [2020] For a short explanation of why the committee made the 2020 recommendation and how it might affect practice, see the rationale and impact section on early invasive versus conservative management for people with unstable angina or NSTEMI. Full details of the evidence and the committee's discussion are in evidence review B: early invasive versus conservative management for unstable angina and NSTEMI. 1.2.21 Offer ticagrelor, as part of dual antiplatelet therapy with aspirin, to people with unstable angina or NSTEMI when PCI is not indicated, unless they have a high bleeding risk. [2020] Ticagrelor is recommended as an option in NICE technology appraisal guidance for treating unstable angina or NSTEMI when PCI is not indicated. For full details, see the guidance on ticagrelor (TA236, 2011). Acute coronary syndromes (NG185) 1.2.22 Consider clopidogrel, as part of dual antiplatelet therapy with aspirin, or aspirin alone, for people with unstable angina or NSTEMI when PCI is not indicated, if they have a high bleeding risk. [2020]
